FDA approves a new drug for a hard-to-treat lung cancer
Neladalkib won accelerated approval for advanced ALK-positive lung cancer that grew back after earlier drugs. In a trial, it shrank tumors in 49% of patients who had taken only alectinib before. It is the seventh approved drug of its kind. The most common side effect was raised liver enzymes.
Where this came from. 2 outlets reported this. We read them, then wrote the sixty words above.